A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)
Status:
Recruiting
Trial end date:
2023-05-30
Target enrollment:
Participant gender:
Summary
A Phase 2 open label study evaluating the safety, tolerability, pharmacokinetics (PK) and
pharmacodynamics (PD) of AL001 in participants with a Granulin mutation or C9orf72 mutation
causative of frontotemporal dementia.